Robinson J B, Sun C C, Bodurka-Bevers D, Im D D, Rosenshein N B
Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Gynecol Oncol. 2000 Aug;78(2):235-41. doi: 10.1006/gyno.2000.5881.
The aim of this study is to determine whether cavitational ultrasonic surgical aspiration (CUSA) is effective and safe for treating vaginal intraepithelial neoplasia (VAIN).
We conducted a retrospective chart review of 46 patients who were treated with CUSA for VAIN in a single gynecologic oncology practice between 1981 and 1999.
At initial presentation, 39% of treated patients had grade I VAIN, 20% had grade II, and 41% had grade III. The mean duration of follow-up from initial CUSA treatment was 21 months. Twenty-nine patients (63%) were initially treated with CUSA, 7 patients (15%) with laser vaporization, 7 patients (15%) with surveillance by Papanicolaou smear, 1 patient (2%) with partial vaginectomy, 1 patient (2%) with 5-fluorouracil, and 1 patient (2%) with loop excision. Patients initially treated with CUSA had a higher percentage of grade III VAIN at diagnosis (48%) than did patients initially treated with other methods (29%). A significantly greater proportion of patients initially treated with CUSA had no recurrence of VAIN (66%) compared with patients initially treated with other methods (0%) (P < 0.0001). A significantly greater proportion of patients who were treated for recurrent disease with CUSA had no further recurrence (52%) compared with patients treated for recurrent disease with other methods (9%) (P < 0.001). No patient treated with CUSA reported adverse effects; 7 patients treated with other methods reported dysuria, burning, and pain.
These initial data suggest that CUSA is a safe and effective method for treating VAIN and may be an appropriate treatment for many patients.
本研究旨在确定超声 cavitational 手术抽吸术(CUSA)治疗阴道上皮内瘤变(VAIN)是否有效且安全。
我们对1981年至1999年间在单一妇科肿瘤实践中接受CUSA治疗VAIN的46例患者进行了回顾性病历审查。
初次就诊时,39%的接受治疗患者为I级VAIN,20%为II级,41%为III级。从初次CUSA治疗开始的平均随访时间为21个月。29例患者(63%)最初接受CUSA治疗,7例患者(15%)接受激光汽化治疗,7例患者(15%)通过巴氏涂片监测,1例患者(2%)接受部分阴道切除术,1例患者(2%)接受5-氟尿嘧啶治疗,1例患者(2%)接受环形切除术。最初接受CUSA治疗的患者在诊断时III级VAIN的比例(48%)高于最初接受其他方法治疗的患者(29%)。与最初接受其他方法治疗的患者(0%)相比,最初接受CUSA治疗的患者中VAIN无复发的比例显著更高(66%)(P < 0.0001)。与接受其他方法治疗复发性疾病的患者(9%)相比,接受CUSA治疗复发性疾病的患者中无进一步复发的比例显著更高(52%)(P < 0.001)。接受CUSA治疗的患者均未报告不良反应;7例接受其他方法治疗的患者报告有排尿困难、烧灼感和疼痛。
这些初步数据表明,CUSA是治疗VAIN的一种安全有效的方法,可能是许多患者的合适治疗方法。